The foundation of the first site in the United States is a key element in GBA Group’s growth strategy in the pharmaceutical sector. With the expansion of pharmaceutical services in the U.S. market, the growing demand from international clients for project support in global clinical trials can be better served.
Steffen Walter, CEO, GBA Group: "The establishment of our first site in the USA is a decisive step for GBA Group in the context of our global growth strategy. The expansion of our pharmaceutical services as a first step in the USA is to be followed by further ones also in other business areas of the GBA Group."
Dr. Sabine Gorynia, EVP Pharma & Medical Devices, GBA Group: “With the presence of our pharma services in the U.S. market, we are responding to the growing demand of our international customers and optimizing our high-quality services with regard to geography and processes. Our focus is on customer proximity, short lead times and smooth project execution."
GBA Group is an international life science services company with over 2,000 employees in 8 countries and a wide range of analytical, logistical and specialist services in the fields of pharmaceuticals, medical devices, cosmetics, chemicals, food, drinking water and the environment. The GBA Group stands for outstanding technical expertise, efficient processes and full focus on customer benefits with regard to its activities in the fields of research, product development, market development and consumer protection. With its services, GBA Group directly and indirectly makes a sustainable contribution to health, the environment and society.
GBA GROUP
Goldtschmidtstraße 5
21073 Hamburg
Telefon: +49 (40) 797172-0
Telefax: +49 (40) 797172-27
https://www.gba-group.com
Head of Corporate Communication
E-Mail: presse@gba-group.de
